Background: A recent randomized trial (the LEAP study) provided evidence that earlier dietary 37 peanut introduction reduces peanut allergy prevalence in high-risk infants. However, questions remain 38 as to how to identify and target the "at risk" population to facilitate timely introduction of peanut 39
Objective: To use population-based infant peanut allergy data to understand feasibility and 40 implications of implementing the LEAP trial intervention 41
Methods: Using the HealthNuts cohort (n=5,300) of 1-year-old infants, we explored the impact of 42 using various criteria to identify infants at high risk of developing peanut allergy, and the implications 43 of skin prick test (SPT) screening prior to peanut introduction 44
Results: Screening all infants with early onset eczema and/or egg allergy could require testing 16% of 45 the population and would still miss 23% of peanut allergy cases. 29% of screened infants would 46 require clinical follow up due to being SPT positive. Around 11% of high-risk infants were excluded 47 from LEAP due to SPT wheal size >4mm to peanut at baseline; data from HealthNuts suggest 80% of 48 these would be peanut allergic on food challenge. There were no life-threatening events among either 49 low-or high-risk infants whose parents chose to introduce peanut at home in the first year of life, or in The recent publication of the LEAP (Learning Early About Peanut Allergy) randomized trial provided 74 direct evidence in high-risk infants (defined as those with severe eczema and/or egg allergy) that 75 delayed introduction of dietary peanut increases the risk of peanut allergy. 1 This is the first 76 randomized trial to describe a prevention strategy for peanut allergy. With reports from the UK, US 77
and Australia that the prevalence of peanut allergy is around 1-3%, [2] [3] [4] and evidence that peanut 78 introduction is delayed in a high proportion of children in these countries, 5, 6 a shift towards earlier 79 introduction of peanut in infants is likely to significantly reduce the burden of peanut allergy. How to 80 achieve this safely and in a cost-effective manner is currently the subject of intense debate. 81
An editorial accompanying publication of the LEAP study suggested "any infant between 4 months 82 and 8 months of age believed to be at risk for peanut allergy should undergo skin-prick testing (SPT) 83 for peanut. If the test results are negative, the child should be started on a [peanut containing diet]… 84 and if the results are positive but show mild sensitivity (i.e., the wheal measures 4 mm or less), the 85 child should undergo a food challenge" (Gruchalla and Sampson). 7 However, no published data are 86 currently available to determine what proportion of the population fall in to the category of "high 87 risk" (thus how many infants would need SPT), what proportion of the high-risk group will develop 88 peanut allergy, and what proportion of all peanut allergy cases occur in high-risk compared with low-89 risk infants. An additional question that arises from the LEAP study is what proportion of infants with 90 a greater than 4mm peanut SPT wheal size (the cut-off used in LEAP to define likely peanut allergy) 91 are truly peanut allergic, and thus whether this group should potentially undergo formal oral food 92 challenge (OFC) prior to recommending peanut avoidance. 93
Interim guidelines have also been released as a result of the LEAP findings, based on consensus 94 among multiple allergy organizations worldwide. These recommend introduction of peanut between 95 4-11 months of age, in infants with severe eczema or egg allergy, in countries where peanut allergy is 96 prevalent. The guidelines also suggest that infants with severe eczema or egg allergy in the first 4-6 97 months of life might benefit from evaluation by an allergist or physician trained in management of 98
allergic disease -including potentially SPT and in-office observed peanut ingestion. 8 Data 99 characterizing SPT and specific IgE (sIgE) values to peanut in the high-risk population of infants, and 100 their relationship to peanut allergy, may help to define the impact on the allergy workforce if this 101 advice is followed, and inform strategies for determining which infants require supervised peanut 102 challenges. Finally, data on the likelihood of reactions, particularly severe reactions, in young infants 103 exposed to peanut in early life is also likely to be useful in addressing these questions. 104
In a recent companion study to the LEAP trial, the EAT (Enquiring About Tolerance) randomized 105 trial compared early introduction (from 3 months of age) of allergenic foods including peanut with 106 standard introduction (from 6 months of age) in infants recruited from the general population. 9 The 107
EAT trial included infants with and without existing allergic disease (eczema) and infants in the 108 control (standard introduction) arm were only required to avoid allergenic foods until 6 months of 109 age. By comparison in the LEAP trial the control arm avoided peanut until age 5 years. Compliance 110 with the intervention in the EAT trial was also lower than in the LEAP trial. There was no evidence of 111 a statistically significant difference in food allergy prevalence at age 1-3 years between the early and 112 standard introduction arms in the primary intention-to-treat analysis. The failure to demonstrate 113 efficacy of early introduction of allergenic foods in EAT could potentially be due to low compliance 114 with the early introduction intervention (consumption of sufficient doses of the allergenic foods), or 115 because the age at allergen introduction in the intervention (median reported age approximately 5 116 months) and control arms (introduced from 6 months, actual age not reported) might not have been 117 different enough to have a biological impact. 118
We aimed to use data from the HealthNuts study, a population-based cohort of 5,300 infants in 119 Australia, to understand the implications and generalisability of the LEAP findings regarding 120 introduction of peanut at the population level. The HealthNuts population provides an ideal 121
Methods 126
HealthNuts study population 127
HealthNuts is a large-scale, population-based cohort study undertaken to assess the prevalence and 128 risk factors for allergic disease in early childhood. 10, 11 Briefly, by using a predetermined population-129 based sampling frame drawn from local government-led immunization clinics in Melbourne, 130
Australia (population four million), infants were recruited while attending one-year-old immunization. 131
All infants aged between 11 and 15 months (inclusive) were eligible for recruitment (74% response 132 rate). Parents completed a questionnaire prior to SPT that included questions about the child's history 133 of peanut consumption and food reactions, and history of eczema (including whether diagnosed, age 134 at diagnosis and history of medication use). 135
Infants were skin prick tested to four foods including peanut and hen's egg (ALK-Abelló, Madrid, 136 Spain), with a positive control (histamine 10 mg/mL), and a negative control (saline) using single-tine 137 lancets on the infant's back. All participants with a detectable wheal to one or more foods were 138 invited to a hospital-based clinic where staff administered repeat SPT and diagnostic OFCs, blinded 139 to the infant's SPT wheal size and history of ingestion. A positive challenge was defined based on 140 pre-specified objective criteria 12 : hives (3 or more hives lasting at least 5 minutes); vomiting; 141 angioedema or anaphylaxis (evidence of circulatory or respiratory involvement), occurring within 2 142 hours of ingestion of the food. We chose any detectable wheal size as our entry criterion to assess the 143 food allergy status of participants to minimize the chances of missing cases of food allergy. A random 144 sample of infants with negative SPT results was also invited to undergo a food challenge (negative 145 controls for the clinic study). SPT was performed with peanut extracts purchased from the same 146 company employed in the LEAP study (ALK-Abelló) and the same lancet device. Blood samples 147 were obtained at clinic attendance and total and sIgE levels to peanut, egg, and other relevant foods Eczema in the first year of life was defined as a diagnosis of eczema, to identify those infants who 157 would already be identified through the medical system. 158
Early moderate/severe eczema was defined as diagnosed eczema starting in the first 6 months of life 159 and treated with topical steroids (either over-the-counter or prescribed). Severity of eczema is defined 160 variably with SCORAD or by ill-defined doctor specific grading so for the purposes of this analysis, 161
we used early onset eczema (before 6 months) and requirement for topical steroid therapy to identify 162 more severe eczema. This would also offer a consistent approach to identifying these infants in 163 practice if the international consensus recommendations are to be adopted. 164
Egg allergy was defined as challenge-proven egg allergy at 1 year of age, in the presence of sIgE to 165 egg detected either by SPT (wheal size ≥ 2mm above saline control) or serum sIgE levels 166 (≥0.35kUA/L). 167
Peanut allergy was defined as challenge proven peanut allergy at 1 year of age. All infants with a 168 positive peanut challenge had peanut sIgE detected by either SPT or serum sIgE. 169
The following definitions were used for risk stratification: 170
High-risk infants were defined as those with either egg allergy or early onset (≤6 months) 171 moderate/severe eczema -these infants would potentially have been eligible for inclusion in the 172 LEAP study, 1 depending on the age of manifestation of egg allergy and the severity of eczema. A 173 comparison of definitions of high risk used in LEAP and accompanying editorial and consensus 174 guidelines is presented in Supplementary Table S1 .
Low-risk infants were defined as those with no egg allergy and no early onset (≤6 months) 176 moderate/severe eczema. It should be noted that this category of infants includes those with late onset 177 or mild forms of eczema. 178
Statistical methods 179
We calculated the proportion of participants in the HealthNuts cohort who: (1) were classified as 180 "high risk" and "low risk"; (2) had challenge-proven peanut allergy in each of the high-risk and low-181 in each SPT or sIgE category was calculated with 95% confidence intervals as above. 193
To investigate factors associated with age at introduction of peanut into the infant diet, the cohort was 194 divided into groups according to the risk factors: family history of eczema or food allergy, infant 195 eczema, and infant history of reaction to egg or milk. Challenge-confirmed egg allergy was not used 196 in this analysis because SPT and challenges to egg occurred after parents had already made the 197 decision on when to introduce peanut to their child. Chi-squared p-values were calculated comparing 198 the distribution of age at peanut introduction in each risk group to the baseline group of "no risk 199
We modelled the potential proportion of peanut allergy cases in the community that might be 201 prevented by applying the LEAP intervention findings to the general population using the following 202 steps: 203
1. We used a hypothetical population of 1,000 infants to represent the general population 204 2. We used the actual prevalence of early onset eczema and/or egg allergy in HealthNuts to split 205 the population into "low-risk" and "high-risk" groups 206 3. We assumed that the LEAP intervention would only be applied to the high-risk group (as per 207 the current consensus guidelines 8 ). We used HealthNuts data to estimate the prevalence of 208 peanut allergy in the low-risk group without intervention (i.e. the HealthNuts observed 209 prevalence of peanut allergy among low-risk infants). 210 4. We used direct percentages from the LEAP study 1 to estimate the proportion of high-risk 211 infants who would have a SPT>4mm to peanut at 4-11 months of age. 212 5. We used HealthNuts data to estimate the proportion of infants with a SPT >4mm who would 213 be peanut allergic (80%) as this data was not available from the LEAP study. 214 6. We used direct percentages from the LEAP control arm to estimate the prevalence of peanut 215 allergy without intervention (17%) and direct percentages from the LEAP intervention arm to 216 estimate the prevalence of peanut allergy with timely peanut introduction between 4-11 217 months (3%), and thus calculated the proportion of cases that could be prevented. 218
Results 220
Characteristics of the HealthNuts study cohort 221
Study participation is shown in Supplementary Figure 1 . Relevant characteristics of the HealthNuts 222 study cohort are described in Table 1 . Our previous work has shown that the HealthNuts participants 223 are generally representative of the infant population of metropolitan Melbourne as compared to the 224 state-mandated Victorian perinatal database. 10 225 Table 2 shows peanut allergy prevalence by eczema and egg allergy status. Overall 84% of the 227 population were classified as "low risk" (no early moderate/severe eczema or egg allergy), with 0.8% 228 of these infants having challenge-confirmed peanut allergy ( Table 2 ). This represents 23% of all 229 peanut allergy cases in the population, who would be missed by targeting only high-risk infants. The 230 remaining 16% of the population were classified as "high risk" by this definition, and 14% of these 231 infants were peanut allergic. This represents 77% of all peanut allergy cases in the population. The 232 highest risk of peanut allergy was in infants with both early moderate/severe eczema and egg allergy 233 (who represented 3.5% of the general population), with 35% of these infants having peanut allergy. 234
Proportion of peanut allergy cases in the general population occurring in high-and low-risk infants 226
Peanut allergy was more common in infants with egg allergy than those without egg allergy, 235 irrespective of their eczema status. 236
Characterizing SPT and sIgE levels to peanut at the population level 237
The distribution of SPT wheal sizes and sIgE levels in the cohort are shown in Figure 1 . Compared to 238 low-risk infants, high-risk infants were more likely to have a detectable wheal on peanut SPT: 29% 239 Using the SPT cut-off values defined in the LEAP study as "likely peanut allergy" (SPT wheal size 246 >4mm), 70.3% (95% CI 54.8, 85.7) of low-risk infants and 80.2% (95% CI 73.0, 87.4) of high-risk 247 infants were allergic on OFC (Table 3) . 248
Prevalence and types of adverse reactions to peanut in the first year of life among infants who 249
introduced peanut at home prior to study participation 250
Overall 30% of infants were introduced to peanut by their parents before 12 months of age 251 (predominantly in the form of peanut butter, data not shown). Infants with eczema or a personal 252 history of reactions to other foods (egg or milk) were less likely to be given peanut before 12 months 253 of age, while a family history of food allergy or eczema had little impact on the age of peanut 254 introduction in the absence of any clinical signs of allergy in the infant (Table 4 ). Only 13% of infants 255 with both early eczema and a history of reaction to milk or egg were introduced to peanut by 12 256 months of age. 257
Of those infants introduced to peanut by their parents by age 12 months, 3% reported a possible 258 reaction, with the majority of these (82%) occurring within 1 hour of ingestion, consistent with IgE-259 mediated reactions. Reactions occurred more commonly in high-risk infants (10.6% vs 1.4%, 260 p<0.001). Table 5 shows the types of reactions. Only one infant had a history consistent with possible 261 anaphylaxis (wheeze/difficulty breathing) with peanut being the reported food causing this reaction 262 (when given at age 12 months), however this child was later shown to tolerate peanut on OFC at age 263 14 months. 264
Prevalence and types of adverse reactions to peanut during hospital-based oral food challenge 265
The most common reaction to peanut OFC, irrespective of SPT wheal size or risk profile, was 266 urticaria ( Table 6 ). Anaphylaxis occurred in 6 challenges (4% of positive challenges), with cases of 267 anaphylaxis seen in both high and low-risk groups. 268
Applying the proportion of peanut allergy cases that may be preventable by applying LEAP 269 intervention to the general population 270
We used the best available data from either HealthNuts or LEAP to model the proportion of peanut 271 allergy cases that might be preventable if the LEAP intervention findings were applied to a 272 hypothetical population of 1,000 infants ( Figure 2) , with the following assumptions: 273 2. 17% of high-risk infants with a 0-4mm wheal would be allergic without intervention (LEAP data 280 -peanut avoidance arm). Note that this is higher than the observed proportion of high-risk infants 281 with a 0-4mm wheal who are peanut allergic in HealthNuts, possibly because of (1) older age in 282 HealthNuts, and/or (2) earlier introduction of peanut in the HealthNuts cohort compared with the 283 LEAP control arm. 284
3. 3% of high-risk infants with a 0-4mm wheal would be allergic with intervention (LEAP data -285 early peanut introduction arm). 286
These assumptions were used to calculate the number of cases of peanut allergy in this constructed 287 population that would be expected with and without intervention, and therefore the proportion of 288 peanut allergy cases that could be prevented through the early introduction of peanut. Note that the 289 proportion of cases that would be expected in low-and high-risk infants in this hypothetical 290 population does not match that observed in HealthNuts, because of the differences between LEAP and 291
HealthNuts described in assumptions 1-3 above. ). If the same magnitude of risk reduction (80%; 6 of 7 cases prevented) could be achieved in 295 low-risk infants, a total of 58% of peanut allergy cases in the community might be prevented (26/45 = 296 58%). This would increase to 64% of cases if timely peanut introduction could also be implemented 297
and was protective in the 20% of infants with a SPT wheal >4mm who are negative on baseline 298 challenge (29/45=64%). If timely peanut introduction was half as successful at preventing peanut 299 allergy in low-risk infants compared to high-risk infants (e.g. 40% of cases prevented instead of 80%), 300
and not implemented in the SPT>4mm group, a total of 51% of peanut allergy cases might be 301 prevented (23/45 = 51%). Our study extends the findings of the LEAP trial 1 to a population-based cohort. We show that using 305 the strict criteria applied in LEAP to select high-risk infants to target early introduction of peanut 306 would miss a sizeable number of peanut allergy cases in the general community. Even using very 307 inclusive criteria to define "high risk" (all infants with early onset eczema and/or egg allergy) to target 308 screening, 23% (95% CI 16.6, 31.3) of peanut allergy cases in the population would still be missed. 309
Furthermore, 29% (95% CI 25.8, 32.4) of these high-risk infants could have a positive SPT. If the 310 current international consensus guidelines were followed, these infants would require clinical follow 311 up to assist with assessment for timely introduction of dietary peanut, which is a large proportion of 312 the general infant population. 313
Using a combination of data from LEAP and HealthNuts to model the potential impact of 314 implementing the LEAP intervention in the wider population, we show that this might only prevent up 315 to 44% of peanut allergy cases if the intervention is restricted to high-risk infants. New strategies in 316 addition to earlier introduction of peanut need to be investigated in future studies to prevent peanut 317 allergy in those infants whose peanut allergy develops too early to benefit from the early introduction 318 intervention. Further research to determine whether earlier introduction of peanut is also beneficial in 319 low-risk infants may also be warranted. The recently published EAT trial compared peanut 320 introduction (along with other allergenic foods) from 3 months (although actual reported median age 321 at introduction was around 5 months) with introduction after 6 months of age in population-recruited 322 infants (with and without eczema). The primary analysis (intention to treat) showed no significant 323 difference in peanut allergy in the two groups, although there was a lower prevalence of peanut 324 allergy in the early introduction group in a secondary per protocol analysis. High-and low-risk infants 325
were not analysed separately. 9 to avoid peanut might be made for these high-risk infants. Identifying peanut tolerant infants through 331 peanut OFC so that they can be included in the earlier introduction of peanut group could improve the 332 proportion of peanut allergy cases prevented, although no data are currently available on the potential 333 beneficial effect of early peanut introduction in preventing peanut allergy later in life in infants with 334 such size SPT. If a cut off is to be used to identify infants who are highly likely to be peanut allergic, 335 and thus reduce the need for food challenges, a more appropriate level might be wheal sizes of 8mm 336 or greater, which has previously been shown to have a 95% positive predictive value for peanut 337 allergy in infants. 13 
338
Our results obtained from a general population cohort also confirm other findings from the high-risk 339 LEAP cohort. We showed that even high-risk infants with SPT wheal sizes of 1-4mm are likely to 340 tolerate peanut if introduced early in life. We also found that positive challenges occurred in some 341 infants with a peanut SPT wheal size of 1-2mm, below the traditional cut-off of 3mm, and in infants 342 with a peanut sIgE level between 0.1-0.34. A further interesting confirmation of the LEAP study was 343 the finding that 34% of high-risk infants with a 0mm SPT to peanut had detectable levels of peanut 344 sIgE -in the LEAP cohort 28% of SPT negative infants had detectable peanut sIgE. 1 
345
The strengths of this study include the careful peanut allergy phenotyping of a large cohort of infants 346 through hospital supervised OFCs, and the fact that the same SPT device, commercially available 347 allergen extract and OFC methodology as LEAP were used. In this context it is striking that predictive 348 values for peanut allergy in the <4mm SPT group were consistent across both studies, despite one 349 study being only high-risk infants and the other population based, with two independent study teams 350 performing the testing. If SPT is to be considered for screening it is therefore likely to be a robust 351
methodology. 352
The findings of this study are likely to be generalizable to the wider Victorian population due to the 353 population-based sampling frame and high participation rate. We have evidence that study 354 participants are generally representative of all births in Victoria from data collected routinely in the 355
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17 perinatal database. 10 In addition, we have previously shown that weighting prevalence estimates, 356 using data on the prevalence of risk factors for peanut allergy in all eligible infants whose parents 357 declined study participation, only marginally altered the prevalence estimate for peanut allergy from 358 3.0% to 2.9%. 2 
359
Despite the large sample size of this study, peanut allergy is a relatively uncommon outcome in the 360 general population. As a result, some SPT and sIgE groups only include a small number of infants, 361 resulting in wide confidence intervals. Our findings need to be interpreted in conjunction with the 362 magnitude of uncertainty around each of the reported estimates. 363
Limitations include that although study participants were peanut challenged within 4-8 weeks of their 364 screening SPT at their 12 month immunization visit, our results pertain to children 12-18 months 365 which is an older age group than that recruited into LEAP. However, despite the difference in age 366 range, key results are remarkably similar across the two cohorts. Additionally different definitions of 367 eczema were used across the cohorts, with infants included in LEAP likely representing more severe 368 eczema cases. Both definitions have limitations since both incorporated the somewhat subjective 369 criteria of parental report of eczema severity and topical steroid use. Defining eczema severity 370 remains problematic so we chose a definition that would identify infants who would be seen through 371 the medical system, with early onset and requirement for topical steroid therapy used to identify more 372 severe eczema. This would also offer a consistent approach to identifying these infants in practice if 373 the international consensus recommendations are to be adopted. Restricting the definition to capture 374 only more severe cases of eczema would increase the number of peanut allergy cases missed. 375
What are the implications of our findings for clinical practice and the potential to implement 376 screening guidelines? As reported in other population-based studies of infants, eczema and egg 377 allergy are common in infancy, 2, 14, 15 although egg allergy appears somewhat more common in 378
Australia than in Europe 16 ; thus even if only high-risk infants were targeted a relatively large 379
proportion of the population would require screening at least in some countries. Consistent with 380 previous studies, 17 we show that both SPT and sIgE to peanut have a strong negative predictive value. 381
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Screening could therefore potentially include some testing in the community setting using peanut sIgE 382 blood tests, perhaps in combination with Ara h2 as a second step, 18 making screening more feasible 383 and reducing the number needing SPT and/or OFC. Furthermore egg allergy was a stronger predictor 384 of peanut allergy than eczema alone; however since less than 25% of infants had introduced egg by 6 385 months of age, this is unlikely to be a helpful early marker for targeting early onset allergic disease for 386 screening as recommended by consensus guidelines. 8 Further studies will need to be done to 387 investigate the potential implications of implementing screening in other countries including the US, 388
which may have different rates of eczema and peanut allergy. 389
An alternative paradigm to screening high-risk infants would be to recommend timely introduction of 390 peanut for all infants irrespective of allergy risk, as per the current Australian guidelines. 19 Our 391 findings provide some reassurance that reactions at home when peanut was introduced as part of a 392 weaning diet before 12 months were uncommon overall, with no (clear) cases of anaphylaxis 393 reported. However, there was evidence of self-selection based on risk, whereby infants with eczema 394 or egg allergy were less likely to introduce peanut before 1 year of age -and this group were more 395 likely to react on introduction -thus it is difficult to predict whether severe reactions would have 396 occurred in peanut was introduced to all high-risk infants at home in an uncontrolled manner. The fact 397 that peanut-allergic infants usually had mild reactions during supervised challenges provides some 398 reassurance. While LEAP did not look at whether early introduction of peanut in low-risk group 399 might lead to reduced risk of peanut allergy, this may be a reasonable recommendation for the 400 population, since data from HealthNuts suggest likelihood of reaction is low and reactions were mild-401 moderate. The publication of the LEAP trial, resulting media coverage, and release of international 402 consensus guidelines stating that delay in peanut introduction might be harmful, is likely to encourage 403 more parents to introduce peanut earlier in infancy, and the HealthNuts study provides baseline data 404 against which to measure changes in timing of peanut introduction and the resulting impact on peanut 405 allergy prevalence. 406
We provide data that the majority of reactions on peanut introduction in young infants are mild, 407 irrespective of whether peanut it is introduced at home or in the hospital, and irrespective of SPT M A N U S C R I P T
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19 wheal size or clinical risk factors. Caution is needed in interpretation of these results since despite the 409 large population recruited the number of peanut-allergic infants was only 150 cases -more severe 410 reactions might still be observed in rare cases. However, in conjunction with findings from the LEAP 411 study, our findings provide reassurance that introducing peanut in infancy is unlikely to lead to severe 412 reactions. In fact, since infants in HealthNuts were already 1 year of age and had predominantly 413 avoided peanut in infancy, thus increasing their likelihood of being peanut allergic, we would expect 414 to see even fewer reactions if peanut was introduction earlier in the first year of life as in LEAP. 415
In conclusion, our results show that large numbers of infants would be affected if screening prior to 416 introduction of peanut was implemented; thus careful consideration of whether and how to target 417 and/or screen infants is required before public health recommendations can be made. Despite the 418 potential to substantially reduce the population prevalence of peanut allergy through timely 419 introduction of peanut high-risk infants, around 20% of peanut allergy cases in the population occur in 420 low-risk infants and an additional 20% of cases occur in infants ineligible for participation due to a 421 SPT wheal size >4mm at recruitment. Additional prevention strategies will be required for these 422 infants. Further population-based intervention trials are required to determine whether timely 423 introduction of peanut is also protective for low-risk infants, and to inform cost-effective analysis of 424 the intervention at the population level as well as cost-effectiveness of various screening strategies. 
Role of the funding source 442
The study sponsors had no involvement in the study design, collection, analysis and interpretation of 443 data, writing of the report or decision to submit the paper for publication. *Infants with a 0mm SPT wheal for peanut included infants selected for challenge based on previous detectable SPT wheal in the community (n=81; 54 of these were <3mm) or as part of a negative control group (0mm skin prick test to peanut in both community and clinic, n=140). Numbers in each analysis differ due to the study design: skin prick testing to peanut was performed as a screening step for all infants, but only infants attending challenge clinic had blood taken for sIgE measurement (83% of those attending clinic agreed to give a blood sample).
Figure 2:
Cases of peanut allergy that may be theoretically preventable by applying the LEAP intervention findings to a general infant population † † We used a hypothetical population of 1,000 infants to represent the general population. At each step, we used the best available observed data from either HealthNuts (blue; this study) or LEAP (black) [1] to calculate the proportion of this hypothetical population that would fall into each group, and the prevalence of peanut allergy in each group. Precedence was given to data from the LEAP study where available.
* The proportion of peanut allergy cases predicted to develop in the 0-4mm SPT group without intervention is the observed proportion of children with peanut allergy in the control arm of the LEAP study. This may be higher than actually observed in a "real world" setting since some of these children might have been introduced to peanut earlier if they were not participating in this randomized trial and thus instructed to avoid peanut until age 5 years. The proportion of peanut allergy cases predicted to develop in the 0-4mm SPT group with intervention is the observed proportion of children with peanut allergy in the intervention arm of LEAP in the intention to treat analysis. ‡ We used figures from the LEAP study [1] to estimate the proportion of high risk infants who would have a SPT>4mm to peanut at 4-11 months of age. This figure (10.6%) is somewhat lower than the proportion of high risk infants in HealthNuts with a SPT>4mm (14.6%), possibly because infants in HealthNuts were older at the time of SPT ( Attended clinic (age 14-16 mths): N=845 (84%) N=329 SPT ≥ 1mm to peanut N=509 SPT 0mm to peanut ‡ † Non-sensitised controls for lab studies. Food challenged to either egg or peanut, and blood collected for sIgE measurement, immunology etc. ‡ 86 of these infants had a peanut SPT ≥1mm at recruitment, thus had peanut OFC despite negative SPT at clinic. The remainder attended clinic due to sensitisation to other foods (not peanut) and did not undergo peanut challenge. 
